Association between miR-27a rs895819 polymorphism and breast cancer susceptibility
Evidence based on 6118 cases and 7042 controls

Yuan Liu, MD\textsuperscript{a,b}, Yi-Fei Gui, MD\textsuperscript{b}, Wen-Yong Liao, MD\textsuperscript{b}, Yu-Qin Zhang, MD\textsuperscript{c}, Xiao-Bin Zhang, MD\textsuperscript{a}, Yan-Ping Huang, MD\textsuperscript{b}, Feng-Ming Wu, MD\textsuperscript{b}, Zhen Huang, MD\textsuperscript{b}, Yun-Fei Lu, MD\textsuperscript{a,b,*}

\textsuperscript{a} Department of Gastrointestinal Gland Surgery, First Affiliated Hospital of Guangxi Medical University, Nanning, \textsuperscript{b} The Fourth Ward of General Surgery, All data generated or analyzed during this study are included in this published \textsuperscript{∗} The authors declare no conflicts of interest to disclose.

Abstract

\textbf{Background:} Polymorphism in miR-27a rs895819 has been associated with breast cancer (BC) risk, but studies have reported inconsistent results. This meta-analysis investigated the possible association between miR-27a rs895819 polymorphism and BC risk.

\textbf{Methods:} PubMed, EMBASE, Google Scholar, and the Chinese National Knowledge Infrastructure (CNKI) databases were systematically searched to identify relevant studies in English and Chinese. Meta-analyses were performed to examine the association between miR-27a rs895819 and BC susceptibility.

\textbf{Results:} A total of 16 case-control studies involving 6118 cases and 7042 controls were included. Analysis using five genetic models suggested no significant association between miR-27a rs895819 polymorphism and BC risk in the total population, or specifically in Asian or Chinese subpopulations. In the Caucasian subpopulation, however, the G-allele and AG genotype at rs895819 were significantly associated with decreased BC risk according to the allelic model (OR 0.90, 95% CI 0.84–0.97, \(P=0.004\)) and heterozygous model (OR 0.89, 95% CI 0.81–0.89, \(P=0.02\)), while the wild-type AA genotype was significantly associated with increased BC risk according to the dominant model (OR 1.13, 95% CI 1.03–1.24, \(P=0.007\)).

\textbf{Conclusion:} These results indicate that among Caucasians, the wild-type AA genotype at rs895819 may confer increased susceptibility to BC, while the G-allele and AG genotype may be protective factors. These conclusions should be verified in large, well-designed studies.

\textbf{Abbreviations:} ARMS = amplification refractory mutation system, BC = breast cancer, HB = hospital-based control group, HRM = high-resolution melting, HWE = Hardy-Weinberg equilibrium, miRNA = microRNA, OR = odds ratio; 95%CI, 95% confidence interval, PB = population-based control group, PCR = polymerase chain reaction, RFLP = restriction fragment length polymorphism.

\textbf{Keywords:} miR-27, polymorphism, breast cancer, meta-analysis

1. Introduction

Breast cancer (BC) is the most commonly diagnosed cancer and the leading cause of cancer death among females. Based on GLOBOCAN, \(\sim 2.1\) million women were newly diagnosed with BC in 2018, accounting for almost \(1\) in \(4\) cancer cases among women.\(^{[1]}\) Causes of sporadic BC are not yet clearly understood, and it is regarded as the more complex form of the disease.

MicroRNAs (miRNAs) are short, noncoding RNA molecules 18 to 25 nucleotides long. A single miRNA can bind to as many as 200 gene targets, and miRNAs are involved in various physiological and pathological cellular pathways, such as acute lymphoblastic leukemia, liver cancer, lung cancer, and BC development.\(^{[2–5]}\) Altogether miRNAs may regulate the expression of approximately one third of protein-coding miRNAs.

The miR-27a is a 78-bp oncogenic miRNA located on chromosome 19, extending from nucleotide 13,836,440 to 13,836,517 (locus 19q13.13). A common polymorphism (rs895819) has been found in the coding genome site of the miR-27a, and it has been associated with many cancers, including BC.\(^{[6]}\) Numerous studies\(^{[7–22]}\) have suggested an association between miR-27a rs895819 polymorphism and BC, but those relatively small studies have reported inconsistent results about
this association. Therefore, we conducted the present meta-analysis including 16 case-control studies involving 6118 cases and 7042 controls to evaluate the possible association between the miR-27a rs895819 polymorphism and BC risk. To the best of our knowledge, this is the largest meta-analysis so far to investigate miR-27a rs895819 polymorphism and BC risk.

2. Materials and methods

2.1. Ethics statement

This study was approved by the Institutional Review Board of First Affiliated Hospital of Guangxi Medical University.

2.2. Search strategy

All clinical and experimental case-control studies of miR-27a rs895819 polymorphism and BC risk published in English and Chinese through August 12, 2020 were identified through systematic searches in PubMed, EMBASE, Google Scholar, and the Chinese National Knowledge Infrastructure (CNKI) databases. The search terms used were: microRNA-27a; miRNA-27a; miR-27a, rs895819; these four terms in combination with polymorphism, polymorphisms, SNP, variant, variants, variation, genotype, genetic or mutation; and all the above terms in combination with breast cancer. Reference lists in identified articles and reviews were also searched manually to identify additional eligible studies.

2.3. Inclusion criteria

To be included in our review and meta-analysis, studies had to use a case-control design to assess the association between the miR-27a rs895819 polymorphism and BC risk, be available as full-text articles and report sufficient data for estimating an odds ratio (OR) with 95% confidence interval (CI), report genotype frequencies, and be conducted in humans.

Studies were excluded if they
1. were duplicates,
2. were irrelevant to BC or the miR-27a rs895819 polymorphism,
3. did not report genotype distributions among groups, or
4. were meta-analyses.

2.4. Data extraction

Two authors (YL and YFG) independently extracted the following data from included studies: first author’s family name, year of publication, ethnicity, type of BC, testing methods, P value for HWE in controls, source of the control group (hospital- or population-based), sample size, matched clinical and pathological parameters, numbers and genotypes of cases and controls, as well as frequencies of genotypes in cases and controls. Discrepancies were resolved by consensus. Only those studies that met the predetermined inclusion criteria were included.

2.4.1. Assessment of methodological quality. To assess the quality of the studies included in this analysis, the Newcastle–Ottawa Scale was applied independently by two assessors (WYL and YQZ).[23] On this scale, a full score is 9 stars, and scores of 5 to 9 stars are considered to be of generally high methodological quality, while scores of 0 to 4 stars are considered to be of poor quality.[24] The quality of all included studies is summarized in Table 2. Any disagreements about scoring were resolved through comprehensive reassessment by the other authors. Only high-quality studies were included in our meta-analysis.

2.5. Description of studies

Search and selection criteria are shown in a flow diagram (Fig. 1). A total of 366 potentially relevant publications up to August 12, 2020 were systematically identified in PubMed, EMBASE, Google Scholar, and CNKI databases. We excluded 331 studies during initial screening of titles and abstracts. Nine studies (3 reviews and 6 studies) were excluded because they were not case-control studies. Another 2 articles were excluded because they did not report precise genotypes. Eight articles were excluded because they investigated polymorphisms in other miRNAs. Therefore, 16 remaining studies[7–22] were included in this meta-analysis based on our search strategy and inclusion criteria. Their characteristics and genotype distributions are summarized in Tables 1 and 2. The distribution of genotypes in controls was consistent with Hardy–Weinberg equilibrium (P > .05) in all but one study.[19] The overall quality of the included studies was high, with a mean score of 6.56 stars on the Newcastle–Ottawa Scale (Table 3).

2.6. Statistical analysis

The unadjusted OR with 95% CI was used to assess the strength of the association between miR-27a rs895819 polymorphism and BC risk based on the genotype frequencies in cases and controls. The significance of pooled ORs was determined using the Z test, with P < .05 defined as the significance threshold. Meta-analysis was conducted using a fixed-effect model when P > .10 for the Q test, indicating lack of heterogeneity among studies; otherwise, a random-effect model was used. All statistical tests for meta-analysis were performed using Review Manager 5.2 (Cochrane Collaboration).

Publication bias was assessed using Begg’s funnel plot and Egger’s weighted regression, with P < .05 considered statistically
significant. These tests were performed using Stata 12.0 (Stata Corp, College Station, TX).

3. Results

3.1. Quantitative data synthesis

The overall results are summarized in Table 4. On the basis of 6118 cases and 7042 controls from 16 studies,[7–22] none of the five genetic models indicated a significant association between the rs895819 polymorphism and BC risk according to any genetic model: allelic model, OR 0.92, 95% CI 0.80 to 1.05, \( P = .21 \); recessive model, OR 0.88, 95% CI 0.66 to 1.12, \( P = .36 \); or heterozygous model, OR 0.86, 95% CI 0.67 to 1.12, \( P = .27 \); dominant model, OR 1.09, 95% CI 0.97 to 1.23, \( P = .14 \); homozygous model, OR 0.87, 95% CI 0.73 to 1.04, \( P = .12 \); heterozygous model, OR 0.92, 95% CI 0.82 to 1.05, \( P = .21 \).

We also meta-analyzed the subgroup of 11 studies[10,11,13–18,20–22] with 2898 cases and 2600 controls from Asian populations. The results showed no evidence of a significant association between rs895819 polymorphism and BC risk for any of the five genetic models (Table 4): allelic model, OR 0.92, 95% CI 0.80 to 1.05, \( P = .22 \); recessive model, OR 0.86, 95% CI 0.67 to 1.12, \( P = .27 \); dominant model, OR 1.08, 95% CI 0.90 to 1.31, \( P = .41 \); homozygous model, OR 0.88, 95% CI 0.66 to 1.16, \( P = .36 \); or heterozygous model, OR 0.91, 95% CI 0.75 to 1.12, \( P = .39 \).

We also meta-analyzed the subgroup of 8 studies[10,11,13–18] involving 2328 cases and 2027 controls from the Chinese population. The results showed no evidence of a significant association between rs895819 polymorphism and BC risk for any of the five genetic models (Table 4): allelic model, OR 0.98,

Table 1

Table 1: Characteristics of studies included in the meta-analysis.

| First author       | Year | Ethnicity | Country | Type of breast cancer | Testing method | \( P \) for HWE | Control source | Sample size (n) | Matched parameters |
|--------------------|------|-----------|---------|-----------------------|----------------|----------------|----------------|-----------------|-------------------|
| Hoffmann[7]        | 2009 | Caucasian | USA     | -                     | MassArray      | .654           | HB             | 434/477         | Benign breast disease |
| Kontorovich[8]     | 2010 | Caucasian | Israel  | -                     | MassArray      | .905           | HB             | 132/149         | BRCA-               |
| Yang[9]            | 2010 | Caucasian | Germany | Familial, BRCA-       | Sequencing     | .142           | PB             | 1189/1416       | Age, residence    |
| Zhang[10]          | 2011 | Asian     | China   | -                     | MassArray      | .605           | PB             | 376/190         | Undetermined       |
| Zhang[11]          | 2012 | Asian     | China   | -                     | PCR-RFLP       | .122           | PB             | 245/243         | Age, sex, residence |
| Catucci[12]        | 2012 | Caucasian | Italy   | Familial, BRCA-       | TaqMan         | .051           | PB             | 1025/1593       | Age                |
| Ma[13]             | 2013 | Asian     | China   | -                     | MassArray      | .605           | HB             | 189/190         | Age                |
| Zhang[14]          | 2013 | Asian     | China   | -                     | Sequencing     | .446           | HB             | 264/255         | Age, sex, residence |
| Wang[15]           | 2014 | Asian     | China   | -                     | PCR-RFLP       | .537           | HB             | 107/219         | Undetermined       |
| He[16]             | 2015 | Asian     | China   | -                     | MassArray      | .839           | PB             | 450/450         | Age                |
| Qi[17]             | 2015 | Asian     | China   | -                     | TaqMan         | .141           | PB             | 321/320         | Age, sex, residence |
| Zhang[18]          | 2015 | Asian     | China   | -                     | MassArray      | .605           | PB             | 376/190         | Undetermined       |
| Morales[19]        | 2016 | Caucasian | Chile   | Familial/Sporadic, BRCA- | Sequencing | .016           | PB             | 440/807         | Age, socioeconomic |
| Nguyen[20]         | 2016 | Asian     | Vietnam | -                     | HRM            | .204           | HB             | 97/100          | Undetermined       |
| Sheikhi[21]        | 2017 | Asian     | Iran    | -                     | PCR-RFLP       | .728           | HB             | 120/120         | Undetermined       |
| Mashaiekhah[22]    | 2018 | Asian     | Iran    | -                     | Tetra-primers ARMS | .063       | HB             | 353/353         | Age, sex, BMI      |

HWE = Hardy–Weinberg equilibrium.

Table 2

Table 2: Genotype distributions of miR-27a rs895819.

| First author       | Year | Ethnicity | Country | Type of breast cancer | Testing method | Sample size (cases/controls) | No. of cases | Allele frequencies in cases | allelic frequencies in controls |
|--------------------|------|-----------|---------|-----------------------|----------------|-------------------------------|--------------|-----------------------------|--------------------------------|
| Hoffmann[7]        | 2009 | Caucasian | USA     | -                     | MassArray      | 434/477                      | 154           | 0.58                        | 0.30/0.70                      |
| Kontorovich[8]     | 2010 | Caucasian | Israel  | -                     | MassArray      | 132/149                      | 98            | 0.51                        | 0.39/0.61                      |
| Yang[9]            | 2010 | Caucasian | Germany | Familial, BRCA-       | Sequencing     | 264/255                      | 102           | 0.51                        | 0.39/0.61                      |
| Zhang[10]          | 2011 | Asian     | China   | -                     | MassArray      | 376/190                      | 196           | 0.52                        | 0.48/0.52                      |
| Zhang[11]          | 2012 | Asian     | China   | -                     | MassArray      | 245/243                      | 60            | 0.52                        | 0.48/0.52                      |
| Catucci[12]        | 2012 | Caucasian | Italy   | Familial, BRCA-       | Sequencing     | 189/190                      | 97            | 0.51                        | 0.49/0.51                      |
| Ma[13]             | 2013 | Asian     | China   | -                     | MassArray      | 376/190                      | 196           | 0.52                        | 0.48/0.52                      |
| Zhang[14]          | 2013 | Asian     | China   | -                     | MassArray      | 245/243                      | 60            | 0.52                        | 0.48/0.52                      |
| Wang[15]           | 2014 | Asian     | China   | -                     | Sequencing     | 189/190                      | 97            | 0.51                        | 0.49/0.51                      |
| He[16]             | 2015 | Asian     | China   | -                     | MassArray      | 376/190                      | 196           | 0.52                        | 0.48/0.52                      |
| Qi[17]             | 2015 | Asian     | China   | -                     | MassArray      | 245/243                      | 60            | 0.52                        | 0.48/0.52                      |
| Zhang[18]          | 2015 | Asian     | China   | -                     | MassArray      | 376/190                      | 196           | 0.52                        | 0.48/0.52                      |
| Morales[19]        | 2016 | Caucasian | Chile   | Familial/Sporadic, BRCA- | Sequencing | 440/807                      | 245           | 0.52                        | 0.48/0.52                      |
| Nguyen[20]         | 2016 | Asian     | Vietnam | -                     | PCR-RFLP       | 376/190                      | 196           | 0.52                        | 0.48/0.52                      |
| Sheikhi[21]        | 2017 | Asian     | Iran    | -                     | MassArray      | 376/190                      | 196           | 0.52                        | 0.48/0.52                      |
| Mashaiekhah[22]    | 2018 | Asian     | Iran    | -                     | MassArray      | 376/190                      | 196           | 0.52                        | 0.48/0.52                      |

HWE = Hardy–Weinberg equilibrium.
Table 3
Methodological quality of studies included in the final analysis, based on the Newcastle–Ottawa Scale for assessing the quality of case–control studies.

| Study       | Adequate definition of patient cases | Representativeness of patient cases | Selection of controls | Definition of controls | Control for important factor or additional factor | Ascertainment of exposure (blinding) | Same method of ascertainment for participants | Non-response rate | Total Score |
|-------------|--------------------------------------|-------------------------------------|-----------------------|------------------------|-----------------------------------------------|-----------------------------------|---------------------------------------------|-----------------|-------------|
| Hoffman[7]  | 1                                    | 1                                   | 0                     | 1                      | 1                                             | 0                                 | 1                                           | 1               | 6           |
| Kontorovich[8] | 1                                    | 1                                   | 0                     | 1                      | 1                                             | 2                                 | 0                                           | 1               | 8           |
| Yang[9]     | 1                                    | 1                                   | 1                     | 1                      | 1                                             | 0                                 | 0                                           | 1               | 6           |
| Zhang[10]   | 1                                    | 1                                   | 1                     | 1                      | 1                                             | 2                                 | 0                                           | 1               | 8           |
| Zhang[11]   | 1                                    | 1                                   | 0                     | 1                      | 1                                             | 1                                 | 0                                           | 1               | 7           |
| Catucci[12] | 1                                    | 1                                   | 1                     | 1                      | 1                                             | 1                                 | 0                                           | 1               | 6           |
| Mu[13]      | 1                                    | 0                                   | 1                     | 1                      | 1                                             | 0                                 | 0                                           | 1               | 6           |
| Zhang[14]   | 1                                    | 1                                   | 0                     | 1                      | 1                                             | 1                                 | 0                                           | 1               | 7           |
| Wang[15]    | 1                                    | 1                                   | 0                     | 1                      | 1                                             | 0                                 | 0                                           | 1               | 5           |
| He[16]      | 1                                    | 1                                   | 1                     | 1                      | 1                                             | 1                                 | 0                                           | 1               | 7           |
| Qi[17]      | 1                                    | 1                                   | 1                     | 1                      | 2                                             | 0                                 | 0                                           | 1               | 8           |
| Zhang[18]   | 1                                    | 1                                   | 1                     | 1                      | 0                                             | 0                                 | 0                                           | 1               | 6           |
| Marzouk[19] | 1                                    | 1                                   | 1                     | 1                      | 2                                             | 0                                 | 0                                           | 1               | 8           |
| Nguyen[20]  | 1                                    | 1                                   | 1                     | 2                      | 0                                             | 0                                 | 0                                           | 1               | 5           |
| Shikanai[21] | 1                                     | 1                                   | 1                     | 1                      | 0                                             | 0                                 | 0                                           | 1               | 5           |
| Mashayekhi[22] | 1                                      | 1                                   | 1                     | 2                      | 0                                             | 0                                 | 0                                           | 1               | 7           |

1 One point was awarded when there was no significant difference in the response rate between the two groups based on a chi-squared test (P > .05).
2 Total score was calculated by adding up the points awarded for each item.

Lastly, we meta-analyzed the subgroup of 3220 cases and 4442 controls in 5 studies[7–9,12,19] from Caucasian populations. The results showed that the G-allele and the AG genotype of rs895819 were both significantly associated with decreased BC risk according to the allelic model (OR 0.90, 95% CI 0.84–0.97, P = .74).

Table 4
Overall meta-analysis of the association between breast cancer and miR-27a polymorphism.

| Genetic model | OR [95% CI] | Z (P) | c2 | df (P) | I² (%) | Analysis model |
|---------------|------------|-------|----|--------|--------|----------------|
| miR-27a rs895819 in total population from 16 case control studies (6118 cases and 7042 controls) | Allelic model (G-allele vs A-allele) | 0.92 [0.84, 1.00] | 0.95 (0.05) | 32.77 | 15 (.005) | 54 Random |
|               | Recessive model (GG vs AG+AA) | 0.88 [0.74, 1.00] | 1.56 (12) | 25.30 | 15 (.05) | 41 Random |
|               | Dominant model (AA vs AG+GG) | 1.09 [0.97, 1.23] | 1.49 (14) | 35.02 | 15 (.002) | 41 Random |
|               | Homozygous model (GG vs AA) | 0.87 [0.73, 1.04] | 1.57 (12) | 25.40 | 15 (.04) | 41 Random |
|               | Heterozygous model (AG vs AA) | 0.92 [0.82, 1.05] | 1.25 (21) | 35.45 | 15 (.002) | 58 Random |
| miR-27a rs895819 in Asian population from 11 case–control studies (2898 cases and 2600 controls) | Allelic model (G-allele vs A-allele) | 0.92 [0.80, 1.05] | 1.23 (22) | 26.46 | 10 (.003) | 62 Random |
|               | Recessive model (GG vs AG+AA) | 0.86 [0.67, 1.12] | 1.11 (27) | 19.81 | 10 (.03) | 50 Random |
|               | Dominant model (AA vs AG+GG) | 1.08 [0.90, 1.31] | 0.82 (41) | 28.02 | 10 (.002) | 64 Random |
|               | Homozygous model (GG vs AA) | 0.88 [0.66, 1.16] | 0.91 (36) | 20.64 | 10 (.02) | 52 Random |
|               | Heterozygous model (AG vs AA) | 0.91 [0.75, 1.12] | 0.86 (39) | 28.70 | 10 (.001) | 65 Random |
| miR-27a rs895819 in Chinese population from 8 case–control studies (2328 cases and 2027 controls) | Allelic model (G-allele vs A-allele) | 0.98 [0.90, 1.08] | 0.35 (74) | 5.81 | 7 (.56) | 0 Fixed |
|               | Recessive model (GG vs AG+AA) | 0.94 [0.77, 1.15] | 0.56 (57) | 5.88 | 7 (.59) | 0 Fixed |
|               | Dominant model (AA vs AG+GG) | 1.00 [0.84, 1.19] | 0.01 (99) | 13.08 | 7 (.07) | 46 Random |
|               | Homozygous model (GG vs AA) | 1.01 [0.82, 1.25] | 0.11 (91) | 1.76 | 7 (.97) | 0 Fixed |
|               | Heterozygous model (AG vs AA) | 0.96 [0.76, 1.20] | 0.38 (70) | 19.62 | 7 (.006) | 64 Random |
| miR-27a rs895819 in Caucasian population from 5 case–control studies (3220 cases and 4442 controls) | Allelic model (G-allele vs A-allele) | 0.90 [0.84, 0.97] | 2.85 (0.04) | 6.30 | 4 (.18) | 37 Fixed |
|               | Recessive model (GG vs AG+AA) | 0.93 [0.80, 1.08] | 0.35 (35) | 4.30 | 4 (.37) | 7 Fixed |
|               | Dominant model (AA vs AG+GG) | 1.13 [1.03, 1.24] | 2.69 (0.07) | 6.67 | 4 (.15) | 40 Fixed |
|               | Homozygous model (GG vs AA) | 0.88 [0.75, 1.03] | 1.63 (10) | 4.64 | 4 (.33) | 14 Fixed |
|               | Heterozygous model (AG vs AA) | 0.89 [0.81, 0.96] | 2.29 (02) | 6.62 | 4 (.16) | 40 Fixed |

95% CI = 95% confidence interval, OR = odds ratio.
$P = .004$, Fig. 2A) and heterozygous model (OR 0.89, 95% CI 0.81–0.89, $P = .02$, Fig. 2B). The wild-type AA genotype was significantly associated with increased BC risk according to the dominant model (OR 1.13, 95% CI 1.03–1.24, $P = .007$, Fig. 2C).

### 3.2. Publication bias

Begg’s funnel plot and Egger’s test were performed to detect potential publication bias in this meta-analysis. No obvious asymmetry was observed in any of the five genetic models based on funnel plots (Fig. 3) or Egger’s test (Fig. 4), suggesting no significant publication bias.

### 4. Discussion

Although several meta-analyses have recently been conducted to explore the association between miR-27a rs895819 polymorphism and BC risk, the results have been inconsistent largely because of limited sample size and ethnic differences among the various populations. Therefore, we performed a meta-analysis of all eligible studies in order to provide a more precise assessment of the association between miR-27a rs895819 polymorphism and BC risk. Our meta-analysis suggests that among Caucasians, the wild-type AA genotype at rs895819 may confer increased susceptibility to BC, while the AG genotype may be a protective factor.

A previous meta-analysis by Chen et al. involving 8 case-control studies with 3697 cases and 5013 controls found that the G-allele at rs895819 was significantly associated with decreased...
BC risk in the total population. Another recent meta-analysis by Zhang et al.\(^{26}\) including 9 case–control studies with 4191 cases and 4776 controls found that rs895819 could decrease BC risk according to the allele contrast and dominant models in the total population. In addition, a meta-analysis by Wu et al.\(^{27}\) including 9 case–control studies with 4499 cases and 5434 controls found that the G-allele at rs895819 is likely associated with decreased BC risk, mainly in Caucasians. A total of 11 case–control studies were included in the three meta-analyses mentioned above.\(^{12,15-27}\) In addition to these studies, the present meta-analysis contained another 5 case–control studies,\(^{7,9,20-22}\) giving a total of 16 case–control studies involving 6118 cases and 7042 controls.

In contrast to the previous meta-analyses,\(^{22,27}\) our work showed no significant association between rs895819 polymorphism and BC risk in the total population or in Asian or Chinese subpopulations. Significant associations were, however, observed in the Caucasian subpopulation, in agreement with the meta-analysis by Wu et al.\(^{27}\) We found that not only the G-allele but also the AG genotype at rs895819 decreased BC risk in Caucasians, while the wild-type AA genotype may confer increased susceptibility to BC in that ethnic group. It is possible that larger samples would allow identification of additional significant correlations.

While the current meta-analysis, to the best of our knowledge, is the largest so far to investigate the possible association between the miR-27a rs895819 polymorphism and BC risk, it is limited by the designs of the included studies. First, the \(P\) value for HWE in one study\(^{11}\) was < .05, suggesting that study population may not be representative of the broader population. Second, BC risk may be affected by age, menopausal status, expression of triple antigen (ER, PR, and Her2), environmental exposure, and other factors, but most studies did not report data on those factors, making it impossible to include them in the present meta-analysis. Third, our exclusion of unpublished data and of papers published in languages other than English or Chinese may have biased our results. Fourth, the studies may show performance bias, attrition bias and reporting bias, although Newcastle-Ottawa scores were at least 5 for all 14 studies, indicating high quality. Thus, additional large and well-designed studies are warranted.

Despite these limitations, the present large meta-analysis provides strong evidence that in the Caucasian population, the wild-type AA genotype at rs895819 may confer increased susceptibility to BC, while the G-allele and AG genotype at rs895819 may be protective factors. These conclusions should be verified in large, well-designed studies.

**Author contributions**

Data curation: Yi-Fei Gui, Xiao-Bin Zhang, Yan-Ping Huang, Feng-Ming Wu, Zhen Huang.

Formal analysis: Wen-Yong Liao, Feng-Ming Wu, Zhen Huang.

Methodology: Yu-Qin Zhang.

Writing – original draft: Yuan Liu.

Writing – review & editing: Yuan Liu, Yun-Fei Lu.

**References**

[1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424.

[2] Tong N, Chu H, Wang M, et al. PrimR-34bc rs498723 polymorphism contributes to acute lymphoblastic leukemia susceptibility in Chinese children. Leuk Lymphoma 2015;1–9.

[3] Wang BS, Lin Z, Xu WX, et al. Functional polymorphisms in microRNAs and susceptibility to liver cancer: a meta-analysis and meta-regression. Genet Mol Res 2014;13:5426–40.

[4] Jia Y, Zang A, Shang Y, et al. MicroRNA-146a rs2910146 polymorphism is associated with susceptibility to non-small cell lung cancer in the Chinese population. Med Oncol 2014;31:194.

[5] Zhang J, He Y, Yu Y, et al. Upregulation of miR-374a promotes tumor metastasis and progression by downregulating LACTB and predicts unfavorable prognosis in breast cancer. Cancer Med 2018;7:3351–62.

[6] Tang W, Yu F, Yao H, et al. miR-27a regulates endothelial differentiation of breast cancer stem like cells. Oncogene 2014;33:2629–38.

[7] Hoffman AE, Zheng TZ, Yi CH, et al. microRNA-miR-196a-2 and breast cancer: a genetic and epigenetic association study and functional analysis. Cancer Res 2009;69:5970–7.

[8] Kontorovich T, Levy A, Korostochlevsky M, et al. Single nucleotide polymorphisms in miRNA binding sites and miRNA genes as breast/ovarian cancer risk modifiers in Jewish high-risk women. Int J Cancer 2010;127:589–97.

[9] Yang R, Schlehe B, Hemminki K, et al. A genetic variant in the pre-miR-27a oncogene is associated with a reduced familial breast cancer risk. Breast Cancer Res Treat 2010;121:693–702.

[10] Zhang P. Polymorphisms of micro RNA and ESR1 genes and their association with triple negative breast cancer risk and prognosis. Peking Union Medical College, 74; 2011.

[11] Zhang M, Jin M, Yu Y, et al. Associations of miRNA polymorphisms and female physiological characteristics with breast cancer risk in Chinese population. Eur J Cancer Care (Engl) 2012;21:274–80.

[12] Carucci I, Verderosi P, Pizzamiglio S, et al. The SNP rs895819 in miR-27a is not associated with familial breast cancer risk in Italians. Breast Cancer Res Treat 2012;133:805–7.

[13] Mu F, Zhang P, Lin D, et al. There is no association between microRNA gene polymorphisms and risk of triple negative breast cancer in a Chinese Han population. PLoS One 2013;8:e60195.

[14] Zhang N, Huo Q, Wang X, et al. A genetic variant in pre-miR-27a is associated with a reduced breast cancer risk in younger Chinese population. Gene 2013;529:125–30.

[15] Wang Y, He Y, Qin Z, et al. Evaluation of functional genetic variants at 6q25.1 and risk of breast cancer in a Chinese population. Breast Cancer Res Treat 2014;146:422.

[16] He B, Fan Y, Xu Y, et al. Associations of polymorphisms in microRNAs with female breast cancer risk in Chinese population. Tumor Biol 2013;34:4575–82.

[17] Qi P, Wang L, Zhou B, et al. Associations of miRNA polymorphisms and expression levels with breast cancer risk in the Chinese population. Genet Med 2013;15:6289–96.

[18] Zhang CY, Wang WQ, Chen J, et al. Reductive 17beta-hydroxysteroid dehydrogenases which synthesize estradiol and inactivate dihydrotestoster-
terone constitute major and concerted players in ER+ breast cancer cells. J Steroid Biochem Mol Biol 2015;150:24-34.

[19] Morales S, Gulppi F, Gonzalez-Hormazabal P, et al. Association of single nucleotide polymorphisms in Pre-miR-27a, Pre-miR-196a2, Pre-miR-423, miR-608 and Pre-miR-618 with breast cancer susceptibility in a South American population. BMC Genet 2016;17:109.

[20] Nguyen PBH, Tran MTH, Nguyen TTN, et al. The relationship between SNP rs895819 (A>G) on miRNA-27a and the breast cancer in the Vietnamese population. Sci Technol Dev J 2016;19:39-49.

[21] Shekari B, Reiisi S. Association between genetic variant in the pre-miR-27a oncogene and risk of breast cancer and metastasis. J Mazandaran Univ Med Sci 2017;27:12-22.

[22] Mashayekhi S, Saedi Saedi H, Salehi Z, et al. Effects of miR-27a, miR-196a2 and miR-146a polymorphisms on the risk of breast cancer. Brit J Biomed Sci 2018;75:76-81.

[23] Wells GA, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses; 2019. Available at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm.

[24] Ownby RL, Crocco E, Acevedo A, et al. Depression and risk for Alzheimer disease: systematic review, meta-analysis. Arch Gen Psychiatry 2006;63:530-8.

[25] Chen M, Fang W, Wu X, et al. Distinct effects of rs895819 on risk of different cancers: an update meta-analysis. Oncotarget 2017;8:75336.

[26] Zhang H, Zhang Y, Zhao X, et al. Association of two microRNA polymorphisms miR-27 rs895819 and miR-423 rs6505162 with the risk of cancer. Oncotarget 2017;8:46969.

[27] Wu J, Wang Y, Shang L, et al. Five common functional polymorphisms in microRNAs and susceptibility to breast cancer: an updated meta-analysis. Genetic Testing Mol Biomarkers 2018;22:350-8.